In a prospective, multicenter study, the 31-GEP identified patients at increased risk of tumor recurrence and added significant prognostic value to AJCC staging. (2024). SKIN The Journal of Cutaneous Medicine, 8(6), s504. https://doi.org/10.25251/skin.8.supp.504